Related Experiment Video

Updated: May 10, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.5K

Olaparib and Durvalumab in Patients with DNA Damage Repair Alterations and Biochemically Recurrent Prostate Cancer

Karen A Autio1,2, Deaglan J McHugh1,2, Dana E Rathkopf1,2

  • 1Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Journal of Immunotherapy and Precision Oncology
|April 24, 2025
PubMed
Summary

No abstract available in PubMed .

Keywords:
ADTPARP inhibitorbiochemical recurrenceimmunotherapyprostate cancer

More Related Videos

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

37.0K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.2K

Related Experiment Videos

Last Updated: May 10, 2025

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
04:07

Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays

Published on: February 24, 2023

1.5K
Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

37.0K
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
10:44

Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage

Published on: January 31, 2018

10.2K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Proofreading01:43

Proofreading

53.5K
Overview
53.5K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

9.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K

Articles linked to this work by shared authors, journal, and citation graph.

Recruitment strategies in the PROMISE Registry: Evaluating institutional outreach, direct-to-patient marketing, and community engagement approaches in a decentralized germline genetic registry.

Contemporary clinical trials communications·2026

Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma.

Exploration of targeted anti-tumor therapy·2026

Real-World Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Treatment Delivery, Immune Reconstitution, and Cardiac Monitoring During High-Dose IL-2.

Current oncology (Toronto, Ont.)·2026

Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer.

Nature reviews. Urology·2026

Structured reasoning failures compromise LLM interpretation of clinical oncology notes.

NPJ digital medicine·2026

B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Impact of Germline BRCA Status on Pathologic Complete Response (pCR) and Outcomes in Early TNBC Treated with Pembrolizumab-Based Neoadjuvant Chemotherapy (KEYNOTE-522 Regimen): A Real-World Study.

Journal of immunotherapy and precision oncology·2026

The Double-Edged Role of Social Media in Modern Healthcare: Awareness, Impact, and Misinformation.

Journal of immunotherapy and precision oncology·2026

Bispecific Antibodies in Solid Tumors: Mechanistic Insights, Clinical Advances, and Future Directions.

Journal of immunotherapy and precision oncology·2026

SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review.

Journal of immunotherapy and precision oncology·2026

Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer.

Journal of immunotherapy and precision oncology·2026

Class II Major Histocompatibility Complex Transactivator (CIITA): A Master MHC-II Regulator Impacting Cancer and Beyond.

Journal of immunotherapy and precision oncology·2026

GATA1 knockdown enhances CD8+ T cell responses and protects against immune escape in cervical squamous cell carcinoma through FGL1 downregulation.

Journal of molecular histology·2026

Tolerability of [161Tb]Tb-SibuDAB in comparison to other PSMA-targeting radioligands in the preclinical setting.

European journal of nuclear medicine and molecular imaging·2026

Efficacy and safety of adjuvant CDK4/6 inhibitors in hormone receptor-positive, HER2-negative early breast cancer: Updated evidence from a systematic review and meta-analysis.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026

Decision-to-outcome analysis of multidisciplinary tumor board-managed NSCLC patients.

Turk gogus kalp damar cerrahisi dergisi·2026

Electronic Structure Engineering at C7 Position of Thieno-Cytosine (thC): Toward Optimal Probe-Adduct Interactions with ABPG in DNA.

The journal of physical chemistry. B·2026

How Functional Variants Reconfigure the Rac2 Conformational Landscape.

The journal of physical chemistry. B·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us